Europäische Union - Finnisch - EMA (European Medicines Agency)

baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - antineoplastiset aineet - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.

Finnland - Finnisch - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - quetiapine hemifumarate - depottabletti - 50 mg - ketiapiini

Finnland - Finnisch - Fimea (Suomen lääkevirasto)

accord healthcare b.v. - quetiapine fumarate - depottabletti - 150 mg - ketiapiini

Europäische Union - Finnisch - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degareliksia - prostatiset kasvaimet - endokriinihoito - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Europäische Union - Finnisch - EMA (European Medicines Agency)

les laboratoires servier - trifluridine, tipiracil hydrochloride - paksusuolen vajaatoiminta - antineoplastiset aineet - colorectal cancerlonsurf is indicated in combination with bevacizumab for the treatment of adult patients with metastatic colorectal cancer (crc) who have received two prior anticancer treatment regimens including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and/or anti-egfr agents. lonsurf is indicated as monotherapy for the treatment of adult patients with metastatic colorectal cancer (crc) who have been previously treated with, or are not considered candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-vegf agents, and anti egfr agentsgastric cancerlonsurf is indicated as monotherapy for the treatment of adult patients with metastatic gastric cancer including adenocarcinoma of the gastroesophageal junction, who have been previously treated with at least two prior systemic treatment regimens for advanced disease.

Europäische Union - Finnisch - EMA (European Medicines Agency)

stemline therapeutics b.v. - elacestrant - rintojen kasvaimet - endokriinihoito - orserdu monotherapy is indicated for the treatment of postmenopausal women, and men, with estrogen receptor (er) positive, her2-negative, locally advanced or metastatic breast cancer with an activating esr1 mutation who have disease progression following at least one line of endocrine therapy including a cdk 4/6 inhibitor.

Europäische Union - Finnisch - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - follitropiini delta - anovulation - sukupuolihormonit ja genitaalijärjestelmään vaikuttavat aineet, - ohjattu munasarjojen stimulaatiota kehittämiseksi useiden munarakkuloiden naisten käynnissä avusteiset lisääntymismenetelmät (art) kuten koeputkihedelmöitys (ivf) tai siittiön injektio (icsi) aikana.

Europäische Union - Finnisch - EMA (European Medicines Agency)

deciphera pharmaceuticals (netherlands) b.v. - ripretinib - ruoansulatuskanavan stromal-kasvaimet - antineoplastiset aineet - qinlock is indicated for the treatment of adult patients with advanced gastrointestinal stromal tumour (gist) who have received prior treatment with three or more kinase inhibitors, including imatinib.

Finnland - Finnisch - Fimea (Suomen lääkevirasto)

krka, d.d., novo mesto - fipronil - sumute iholle, liuos - 2.5 mg/ml - fiproniili

Finnland - Finnisch - Fimea (Suomen lääkevirasto)

zoetis animal health aps - erysipelothrix rhusiopathiae, inactivated, strain b-7, serotype 2, porcine parvovirus, inactivated, strain s-80 - injektioneste, emulsio - inaktivoitu sian parvovirus -rokote + inaktivoitu erysipelothrix rokote